Feasibility of disease terminology systems for mapping orphan conditions and therapeutic indications of designated orphan medicines in the European Union

Regulatory data concerning orphan conditions and therapeutic indications of designated orphan medicines seem to be best covered by SNOMED CT. However, which disease terminology system best facilitates systematic evaluation and communication about development and authorisation of designated orphan medicines also depends on the specific use case. Given the frequent use of SNOMED CT in healthcare settings, it may also facilitate interoperability between regulatory and healthcare data, while for example ICD-11 may be better suited to generate statistics concerning drug development for rare diseases.

Authors

Institutions

Publication Details

Journal
European Journal of Pharmaceutical Sciences
Published
2024-08-05
DOI
https://doi.org/10.1016/j.ejps.2024.106871
Citations
1
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.55
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Feasibility of disease terminology systems for mapping orphan conditions and therapeutic indications of designated orphan medicines in the European Union

Violeta Stoyanova‐Beninska, Anna M.G. Pasmooij, Hubert G. M. Leufkens, Lourens T. Bloem et al.
1 citations
European Journal of Pharmaceutical Sciences
Genomics and Rare Diseases
0.55
article

Feasibility of disease terminology systems for mapping orphan conditions and therapeutic indications of designated orphan medicines in the European Union

Violeta Stoyanova‐Beninska, Anna M.G. Pasmooij, Hubert G. M. Leufkens, Lourens T. Bloem, Keerti D Jadoenathmisier, Inge M Soons
article en
1 citations

Abstract

Regulatory data concerning orphan conditions and therapeutic indications of designated orphan medicines seem to be best covered by SNOMED CT. However, which disease terminology system best facilitates systematic evaluation and communication about development and authorisation of designated orphan medicines also depends on the specific use case. Given the frequent use of SNOMED CT in healthcare settings, it may also facilitate interoperability between regulatory and healthcare data, while for example ICD-11 may be better suited to generate statistics concerning drug development for rare diseases.

European Journal of Pharmaceutical SciencesVol. 202
Utrecht University (NL), Pharmo Institute (NL), Nationaal ICT Instituut in de Zorg (NL), Medicines Evaluation Board (NL)
Openalex Percentile: Top 27%
Genomics and Rare Diseases
0.55
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.